Cargando…

Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-controlled, crossover study

BACKGROUND: Glucocorticoids (GCs), such as prednisone, are the standard of care for several inflammatory and immunologically mediated diseases, but their chronic systemic administration is severely limited by serious adverse effects that are both dose and time dependent. Short-term treatment (7–14 d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fleishaker, Dona L., Mukherjee, Arnab, Whaley, Fredrick S., Daniel, Shanthini, Zeiher, Bernhardt G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947329/ https://www.ncbi.nlm.nih.gov/pubmed/27424036 http://dx.doi.org/10.1186/s12891-016-1135-3

Ejemplares similares

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
por: van der Heijde, Désirée, et al.
Publicado: (2017)

Improved disease activity with fosdagrocorat (PF‐04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study
por: Stock, Thomas, et al.
Publicado: (2017)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial
por: Fleishaker, Dona L, et al.
Publicado: (2012)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
por: Cui, Yimin, et al.
Publicado: (2013)

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects
por: Frost, Charles, et al.
Publicado: (2018)

Long-range critical exponents near the short-range crossover
por: Behan, Connor, et al.
Publicado: (2017)

Stable Bipolar Patient Switched to Mania following Clinical Doses of Prednisone
por: Panwar, Vikram, et al.
Publicado: (2011)

Low-Dose Prednisone Therapy is Efficacious in Treating Painful Subacute Thyroiditis
por: Shakir, Mohamed K M, et al.
Publicado: (2021)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study
por: Li, Haiyan, et al.
Publicado: (2020)

In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF‐00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor
por: Ripp, Sharon L., et al.
Publicado: (2017)

First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort
por: Ruiz-Irastorza, G, et al.
Publicado: (2016)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
Publicado: (2014)

Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese Subjects
por: Li, Haiyan, et al.
Publicado: (2020)

Comparison of the pharmacokinetics and pharmacodynamics of YH4808 in healthy subjects for defining an appropriate dosing regimen
por: Yoon, Sukyong, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Colistin Methanesulfonate in Healthy Chinese Subjects after Multi-Dose Regimen
por: Fan, Yaxin, et al.
Publicado: (2022)

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
por: Besarab, Anatole, et al.
Publicado: (2015)

A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects
por: Liu, Chao, et al.
Publicado: (2019)

Effect of short-term prednisone on beta-cell function in subjects with type 2 diabetes mellitus and healthy subjects
por: Shah, Monica, et al.
Publicado: (2020)

Effects of Rapamycin Combined with Low Dose Prednisone in Patients with Chronic Immune Thrombocytopenia
por: Li, Jiaming, et al.
Publicado: (2013)

Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab
por: van der Veer, Tjeerd, et al.
Publicado: (2021)

Four Case Reports of Acute Psychosis Secondary to Low Doses of Prednisone/Prednisolone
por: Lesko, Aquila, et al.
Publicado: (2021)

Dose-Response of Paraxanthine on Cognitive Function: A Double Blind, Placebo Controlled, Crossover Trial
por: Xing, Dante, et al.
Publicado: (2021)

A Single 60.000 IU Dose of Erythropoietin Does Not Improve Short-Term Aerobic Exercise Performance in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
por: Haider, Thomas, et al.
Publicado: (2020)

Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects
por: Wang, Shining, et al.
Publicado: (2021)

Single and Repeated Doses of EGb 761(®) do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects
por: Hoerr, Robert, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects
por: He, Xuemei, et al.
Publicado: (2022)

Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study
por: Landry, Ishani, et al.
Publicado: (2022)

A scaling theory for the long-range to short-range crossover and an infrared duality
por: Behan, Connor, et al.
Publicado: (2017)

Dose-Dependent Delay of the Hypoglycemic Effect of Short-Acting Insulin Analogs in Obese Subjects With Type 2 Diabetes: A pharmacokinetic and pharmacodynamic study
por: Gagnon-Auger, Maude, et al.
Publicado: (2010)

A Double‐Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects
por: Hussaini, Azra, et al.
Publicado: (2019)

Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study
por: Fahy, William A, et al.
Publicado: (2021)

Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects
por: Vinson, Joe A, et al.
Publicado: (2012)

Effects of different phenylcapsaicin doses on neuromuscular activity and mechanical performance in trained male subjects: a randomized, triple-blinded, crossover, placebo-controlled trial
por: Jiménez-Martínez, Pablo, et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Considerations in Antimalarial Dose Optimization
por: White, Nicholas J.
Publicado: (2013)

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

Repeated-Dose Pharmacodynamics of Pimobendan in Healthy Cats
por: Sugimoto, Keisuke, et al.
Publicado: (2022)

The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity
por: Cimmino, Marco A, et al.
Publicado: (2011)

Low-dose modified-release prednisone in axial spondyloarthritis: 3-month efficacy and tolerability
por: Bandinelli, Francesca, et al.
Publicado: (2016)

Chronotherapy with low-dose modified-release prednisone for the management of rheumatoid arthritis: a review
por: Beltrametti, Stefano Paolo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6dg1pqsoses32ngg6lh43d9aea